Table 2. BCVA (logMAR) at the pre-lockdown and follow-up visits among the control and delayed groups.

	Pre-Lockdown BCVA (logMAR)	Follow up BCVA (logMAR)	Significance
Control Group (n = 90)	0.404	0.413	p = 0.70
nAMD (n = 57)	0.391	0.419	p = 0.20
DME (n = 30)	0.417	0.449	p = 0.40
RVO (n = 3)	0.333	0.272	Not significant
Delayed Group (n = 77)	0.631	0.767	p = 0.007
nAMD (n = 36)	0.729	0.853	p = 0.04
DME (n = 34)	0.544	0.722	p = 0.06
RVO (n = 7)	0.555	0.549	Not significant

There was no significant difference between the BCVA at the pre-lockdown (0.404) and follow-up (0.413) in the control group (p = 0.70). BCVA worsened in the delayed group from 0.631 (pre-lockdown) to 0.767 (follow-up). This was statistically significant (p = 0.007). Subgroup analysis was also performed for nAMD and diabetes in both groups and there was a trend towards worsening BCVA in the delayed group.